Patents by Inventor Dmitry Bulavin

Dmitry Bulavin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR INHIBITING WIP1
    Publication number: 20090074724
    Abstract: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.
    Type: Application
    Filed: October 20, 2008
    Publication date: March 19, 2009
    Applicant: Government of the United States of America, Represented by the Secretary, Department of Health
    Inventors: Dmitry Bulavin, Ettore Appella, Albert J. Fornace, JR., Anne Kallioniemi
  • Materials and methods for inhibiting Wip1
    Patent number: 7456268
    Abstract: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.
    Type: Grant
    Filed: October 8, 2007
    Date of Patent: November 25, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dmitry Bulavin, Ettore Appella, Albert J. Fornace, Jr., Anne Kallioniemi
  • MATERIALS AND METHODS FOR INHIBITING WIP1
    Publication number: 20080081065
    Abstract: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.
    Type: Application
    Filed: October 8, 2007
    Publication date: April 3, 2008
    Applicants: and Human Services
    Inventors: Dmitry BULAVIN, Ettore APPELLA, Albert FORNACE, Anne KALLIONIEMI
  • Materials and methods for inhibiting wip1
    Publication number: 20050037360
    Abstract: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor, a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.
    Type: Application
    Filed: March 21, 2003
    Publication date: February 17, 2005
    Inventors: Dmitry Bulavin, Ettore Appella, Albert Fornace Jr., Anne Kallioniemi
  • Materials and methods for inhibiting Wip1
    Publication number: 20040167189
    Abstract: The invention provides a method of treating cancer in a mammal that expresses the same level or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, and a method of inhibiting Wip1 in a cell. The invention also provides pharmaceutical compositions comprising a compound selected from the group consisting of Compounds A-N, and a method of making a cancer therapeutic composition. Also provided is a compound selected from the group consisting of Compounds A-N, a method of screening a compound for Wip1-inhibiting activity, and a method of determining the efficacy with which a test compound inhibits Wip1.
    Type: Application
    Filed: March 12, 2004
    Publication date: August 26, 2004
    Applicant: The Government of the U.S.A., as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Dmitry Bulavin, Galina Belova, Albert J. Fornace